Loading clinical trials...
Loading clinical trials...
Establishing Biobank in a Cohort Study for Hypertensive Patients in Guangdong Province(GDP Study)
Hypertension is the most common chronic diseases and a most important risk factor for cardiovascular and cerebrovascular diseases, and also a substantial public health problem. The purpose of the study is to investigate the association between biomarkers and adverse outcomes in patients with hypertension.
Study population includes subjects who are hypertension, of any race or ethnicity, 18 or older years of age, and have provided written informed consent to provide whole blood specimens at one or more study visits. Physical examination, questionnaire survey and biological sample collection will be conducted at baseline and the incidence of all-cause and cardiovascular mortality will be investigated during follow-up.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Guangdong Cardiovascular Institute
Guangzhou, Guangdong, China
Start Date
January 1, 2020
Primary Completion Date
December 31, 2022
Completion Date
December 31, 2050
Last Updated
January 13, 2020
50,000
ESTIMATED participants
Non-interventional study
OTHER
Lead Sponsor
Guangdong Provincial People's Hospital
NCT02417740
NCT07073820
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07480265